Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
21
12
2022
accepted:
02
08
2023
medline:
27
9
2023
pubmed:
8
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performed RNA sequencing (n = 97) and multiplexed immunofluorescence (n = 122) on chemo-naive and postchemotherapy (post-CTX) resected patient samples (chemoradiotherapy excluded) to define the impact of neoadjuvant chemotherapy. Transcriptome analysis combined with high-resolution mapping of whole-tissue sections identified GATA6 (classical), KRT17 (basal-like) and cytochrome P450 3A (CYP3A) coexpressing cells that were preferentially enriched in post-CTX resected samples. The persistence of GATA6
Identifiants
pubmed: 37679568
doi: 10.1038/s43018-023-00628-6
pii: 10.1038/s43018-023-00628-6
pmc: PMC10518256
doi:
Substances chimiques
Cytochrome P-450 CYP3A
EC 1.14.14.1
Adjuvants, Immunologic
0
Keratin-17
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1362-1381Informations de copyright
© 2023. The Author(s).
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
doi: 10.3322/caac.21708
pubmed: 35020204
Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513–5518 (2009).
pubmed: 19858379
doi: 10.1200/JCO.2009.24.2446
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
doi: 10.1056/NEJMoa1304369
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
pubmed: 21561347
doi: 10.1056/NEJMoa1011923
Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200–1210 (2004).
pubmed: 15028824
doi: 10.1056/NEJMoa032295
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).
pubmed: 20823433
doi: 10.1001/jama.2010.1275
Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).
doi: 10.1016/S0140-6736(16)32409-6
pubmed: 28129987
Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).
pubmed: 30575490
doi: 10.1056/NEJMoa1809775
Xu, Z. et al. Clinical impact of molecular subtyping of pancreatic cancer. Front. Cell Dev. Biol. 9, 743908 (2021).
doi: 10.3389/fcell.2021.743908
Ghaneh, P. et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol. 38, 4505 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.4505
Katz, M. H. G. et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J. Clin. Oncol. 39, 377 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.377
Versteijne, E. et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J. Clin. Oncol. 40, 1220–1230 (2022).
pubmed: 35084987
doi: 10.1200/JCO.21.02233
Hackert, T. et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann. Surg. 264, 457–463 (2016).
pubmed: 27355262
doi: 10.1097/SLA.0000000000001850
Maeda, S. et al. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Surgery 171, 1379–1387 (2022).
pubmed: 34774289
doi: 10.1016/j.surg.2021.10.015
Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545–557 (2016).
pubmed: 26615328
doi: 10.1016/S0140-6736(15)00986-1
Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178–1191 (2022).
pubmed: 35902743
pmcid: 10290535
doi: 10.1038/s41588-022-01134-8
Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119–6137 (2021).
pubmed: 34890551
pmcid: 8822455
doi: 10.1016/j.cell.2021.11.017
Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19, 439–457 (2021).
pubmed: 33845462
doi: 10.6004/jnccn.2021.0017
Amin, M. B. et al. (eds) AJCC Cancer Staging Manual 8th edn (Springer, 2017).
Grünwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577–5592 (2021).
pubmed: 34644529
doi: 10.1016/j.cell.2021.09.022
Michelakos, T. et al. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. J. Natl Cancer Inst. 113, 182–191 (2021).
pubmed: 32497200
doi: 10.1093/jnci/djaa073
Mota Reyes, C. et al. Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells. Clin. Cancer Res. 26, 220–231 (2020).
pubmed: 31585935
doi: 10.1158/1078-0432.CCR-19-1864
Peng, H. et al. Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in patients with pancreatic cancer. Clin. Cancer Res. 27, 6761–6771 (2021).
pubmed: 34593529
pmcid: 8678309
doi: 10.1158/1078-0432.CCR-21-0998
Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168–1178 (2015).
pubmed: 26343385
pmcid: 4912058
doi: 10.1038/ng.3398
Rashid, N. U. et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin. Cancer Res. 26, 82–92 (2020).
pubmed: 31754050
doi: 10.1158/1078-0432.CCR-19-1467
Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011).
pubmed: 21460848
pmcid: 3755490
doi: 10.1038/nm.2344
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
pubmed: 26909576
doi: 10.1038/nature16965
Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231–240 (2020).
pubmed: 31932696
doi: 10.1038/s41588-019-0566-9
Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344–1354 (2018).
pubmed: 29288237
doi: 10.1158/1078-0432.CCR-17-2994
O’Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901–4910 (2020).
pubmed: 32156747
doi: 10.1158/1078-0432.CCR-19-3724
Brunton, H. et al. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep. 31, 107625 (2020).
pubmed: 32402285
pmcid: 9511995
doi: 10.1016/j.celrep.2020.107625
Kloesch, B. et al. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut 71, 766–777 (2021).
Martinelli, P. et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 66, 1665–1676 (2017).
pubmed: 27325420
doi: 10.1136/gutjnl-2015-311256
Kalisz, M. et al. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. EMBO J. 39, e102808 (2020).
pubmed: 32154941
pmcid: 7196917
doi: 10.15252/embj.2019102808
O’Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901–4910 (2020).
pubmed: 32156747
doi: 10.1158/1078-0432.CCR-19-3724
Roa-Peña, L. et al. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci. Rep. 9, 11239 (2019).
pubmed: 31375762
pmcid: 6677817
doi: 10.1038/s41598-019-47519-4
Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat. Med. 22, 278–287 (2016).
pubmed: 26855150
pmcid: 4780258
doi: 10.1038/nm.4038
Ding, X. & Kaminsky, L. S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43, 149–173 (2003).
pubmed: 12171978
doi: 10.1146/annurev.pharmtox.43.100901.140251
Krishna, D. R. & Klotz, U. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26, 144–160 (1994).
pubmed: 8162658
doi: 10.2165/00003088-199426020-00007
Pavek, P. & Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 9, 129–143 (2008).
pubmed: 18288955
doi: 10.2174/138920008783571774
Hwang-Verslues, W. W. & Sladek, F. M. HNF4α—role in drug metabolism and potential drug target? Curr. Opin. Pharmacol. 10, 698–705 (2010).
pubmed: 20833107
pmcid: 2981672
doi: 10.1016/j.coph.2010.08.010
Buck, E. et al. Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncol. Lett. 17, 3890–3898 (2019).
pubmed: 30881507
pmcid: 6403523
Greenhalf, W. et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J. Natl Cancer Inst. 106, djt347 (2014).
pubmed: 24301456
doi: 10.1093/jnci/djt347
Aughton, K. et al. hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA. Cancers 13, 5758 (2021).
pubmed: 34830914
pmcid: 8616255
doi: 10.3390/cancers13225758
Okamura, Y. et al. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: a collaborative study from the JASPAC 01 trial. Cancer Rep. 5, e1507 (2021).
Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112–1129 (2018).
pubmed: 29853643
pmcid: 6125219
doi: 10.1158/2159-8290.CD-18-0349
Santos, A. et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6, 2012–2020 (2000).
pubmed: 10815927
Bailey, P. et al. Refining the treatment of pancreatic cancer from big data to improved individual survival. Function 4, zqad011 (2023).
pubmed: 37168490
pmcid: 10165547
doi: 10.1093/function/zqad011
Candido, J. B. et al. CSF1R
pubmed: 29719257
pmcid: 5946718
doi: 10.1016/j.celrep.2018.03.131
Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845 (2016).
pubmed: 27265504
pmcid: 4912354
doi: 10.1016/j.ccell.2016.04.014
Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).
pubmed: 36781852
pmcid: 9925748
doi: 10.1038/s41467-023-36296-4
Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat. Cancer 1, 1097–1112 (2020).
pubmed: 34296197
pmcid: 8294470
doi: 10.1038/s43018-020-00121-4
Brierley, J. D., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours (John Wiley & Sons, 2017).
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
pubmed: 25557080
doi: 10.1016/j.cell.2014.12.021
Janes, K. A. An analysis of critical factors for quantitative immunoblotting. Sci. Signal. 8, rs2 (2015).
pubmed: 25852189
pmcid: 4401487
doi: 10.1126/scisignal.2005966
Nilles, J., Weiss, J. & Theile, D. Crystal violet staining is a reliable alternative to bicinchoninic acid assay-based normalization. Biotechniques 73, 131–135 (2022).
pubmed: 36000337
doi: 10.2144/btn-2022-0064
Roessler, S. et al. Integrative genomic and tanscriptomic characterization of matched primary and metastatic liver and colorectal carcinoma. Int. J. Biol. Sci. 11, 88–98 (2015).
pubmed: 25552933
pmcid: 4278258
doi: 10.7150/ijbs.10583
Xie, L. et al. Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. Oncotarget 10, 7276–7287 (2019).
pubmed: 31921387
pmcid: 6944451
doi: 10.18632/oncotarget.27399
Reisinger, E. et al. OTP: an automatized system for managing and processing NGS data. J. Biotechnol. 261, 53–62 (2017).
pubmed: 28803971
doi: 10.1016/j.jbiotec.2017.08.006
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658
pmcid: 403769
doi: 10.1101/gr.1239303
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).
pubmed: 29141660
pmcid: 5688663
doi: 10.1186/s13059-017-1349-1
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
doi: 10.1084/jem.20162024
Hamilton, N. E. & Ferry, M. ggtern: ternary diagrams using ggplot2. J. Stat. Softw. 87, 1–17 (2018).
doi: 10.18637/jss.v087.c03
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532
pmcid: 5802054
doi: 10.1186/s13059-017-1382-0